

***In-Silico* Analysis of Natural Products that Modulates Enzymes of Diabetic Target**

Babita Aryal¹, Saroj Basnet², Bishnu P. Marasini³, Karan Khadayat¹, Darbin Kumar Poudel¹, Ganesh Lamichhane¹, Prakriti Budhathoki¹, Purushottam Niraula¹, Sonika Dawadi¹, Rishab Marahatha¹, Sitaram Phuyal¹, and Niranjan Parajuli^{1*}

Specifications Table

Subject	Pharmaceutical Science
Specific subject area	Interdisciplinary field includes organic chemistry, biochemistry, and biology. Drug design and discovery from plant sources.
Type of data	Tables Figures
How data were acquired	MOE 2009 and GOLD V 4.51
Data format	Raw and Analysed
Parameters for data collection	Gold Fitness score, energetic values and interactions of protein with the ligand.
Description of data collection	The Proteins were collected from RCSB protein bank. The secondary metabolites structures were obtained from Pubchem online database. The docking was done using GOLD software.
Data source location	https://www.rcsb.org/ https://pubchem.ncbi.nlm.nih.gov/
Data accessibility	PDB files of the chosen enzyme targets are publically available at https://www.rcsb.org/ Tables and Figures of the docking are accessible in the article.

Value of the Data

- The screening procedure enable the researchers to rapidly identify active natural compounds which can modulate a particular biochemical pathway.
- The screening results help to study the interaction/role of active metabolites in a particular biochemical process at cellular level and provide preliminary ideas for drug design development
- By using this *in-silico* docking data, novel synthetic analogues with improved bioactivity and minimized side effects can be developed against these targets and research time can be minimized considerably.
- We select these 23 metabolites because these are abundant in nature and well explored. Among these metabolites, the compounds which show best affinity for various targets are shortlisted.
- The data is also useful for research scholars who does not have the sufficient software and hardware requirements which not affordable by them.
- Research scholars, researchers in pharmaceutical chemistry, Medicinal Chemistry, Drug Design Industry can be benefit from the data.

Table 1S. List of Targets showing the PDB ID, resolution and description of the proteins selected for docking with complexed inhibitor.

S.No	PDB ID	Resolution (Å)	Description
1	1LPB	2.46	Structure of pancreatic lipase -colipase complex [1]
2	1US0	0.66	Human Aldose Reductase in complex with NADP+ and the inhibitor IDD594 [2]
3	5U3A	0.95	The crystal structure of Human pancreatic alpha amylase [3]
4	5NN8	2.45	Crystal structure of Human lysosomal acid-alpha-glucosidase complex with Acarbose [4]

Table 2S. Inhibition of lipase by secondary metabolites

Natural Source	Secondary metabolite	IC ₅₀ (µM)	Reference
<i>Penicillium purpurogenum</i> IMM 003	Purpurolide F	1.22	[1]
	Purpurolide D	6.5	
	Purpurolide E	7.88	
<i>Xestospongia testudinaria</i> (sponges)	Methyl xestospongic ester	3.11	[2]
<i>Caralluma hexagona</i> Lavrano (aerial part)	12,20-di-O-benzoyl-3β,8β,12β,14β,20-pentahydroxy-(20R)-pregn-5-ene-3-O-β-D-glucopyranosyl-(1→4)β-D-digitalosiden	23.59	[3]
<i>Polygonum aviculare</i> L. whole	Quercetin (competitive inhibition)	53.05	[4]
	Kaempferol (competitive inhibition)	79.38	
	Myricitrin (non-competitive or mixed)	92.85	
	Quercitrin (non-competitive or mixed)	100.56	
	Avicularin (non-competitive or mixed)	141.84	
<i>Trigonella foenum-graecum</i> (seeds)	Schaftoside	230.29	[5]
	Vicenin-1	336.7	
	Isoschaftoside	584.59	

Current medication: Sorbinil, Fidarestat, Alrestatin, Epalrestat, Tolrestat, Zenarestat.

Note: Some IC₅₀ values are adjusted in terms of molarity to make the comparison convenient.

Table 3S. Inhibition of aldose reductase by secondary metabolites

Enzyme	Natural Source	Secondary metabolite	IC ₅₀ (μ M)	Reference
Rat lens aldose reductase	<i>Cuminum cyminum</i> (seeds)	Cuminaldehyde	5.37	[6]
Rat lens aldose reductase	<i>Melastoma sanguineum</i>	2,"4"-O-diacetylquercitrin	0.077	[7]
Rat lens aldose reductase	<i>Artemisia montana</i> (whole plant)	Luteolin	0.19	[8]
		Hyperoside	1.85	
		Chlorogenic acid	4.36	
		3,5-Di-O-caffeoylquinic acid	5.37	
Rat lens aldose reductase (RLAR)			0.3	
Human recombinant aldose reductase(rhAR)	<i>Xanthium strumarium</i> (fruit)	Methyl-3,5-di-O-Caffeoylquininate	0.67	[9]
Rat lens aldose reductase Human recombinant aldose reductase			0.45	
		Desmethylanhydroicaritin	0.95	
	<i>Sophora flavescens</i> (roots)	8-lavandulylkaempferol	0.79	[10]
			3.8	
Recombinant human aldose reductase	<i>Rhus verniciflua</i>	Butein	0.5	[11]
Rat lens aldose reductase	<i>Smilax china L.</i> (stems)	Quercitrin	0.56	[12]
		3-O-Caffeoylquinic acid	0.6	
		Isoscutellarein-8-O-rhamnoside	17	
		4-O-Caffeoylquinic acid	20.1	
Rat lens aldose reductase	<i>Belamcanda chinensis</i> (rhizomes)	Tectorigenin	1.08	[13]
		Tectoridin	1.12	
Rat lens aldose reductase	<i>Abeliophyllum distichum</i> (leaves)	Acteoside	1.39	[14]
Rat lens aldose reductase	<i>Chrysanthemum indicum</i>	(2R)-eriodictyol 7-O- β -D-glucopyranosiduronic acids	1.5	[15]
		(2S)-eriodictyol 7-O- β -D-glucopyranosiduronic acids	2.1	
Rat lens aldose reductase	<i>Colocasia esculenta</i>	Orientin	1.65	[16]

Supplementary Materials

reductase		Isoorientin	1.92	
	<i>Artemisia princeps</i>	1,3,5-tri-O-caffeoylquinic acid	1.78	
Rat lens aldose reductase	(Aerial part)	3,4,5-tri-O-caffeoylquinic acid	1.95	[17]
		3,4-di-O-caffeoylquinic acid	2.4	
Rat lens aldose reductase	<i>Glycyrrhiza uralensis</i> (roots)	Semilicoisoflavone B	1.8	[18]
			10.6	
Bovine lens aldose reductase	<i>Ocimum basilicum</i> (Aerial)	7-(3-hydroxypropyl)-3-methyl-8- β -O-d-glucoside-2H-chromen-2-one	2.095	[19]
Rat lens aldose reductase	<i>Maackia amurensis</i> (bark)	Chlorogenic acid	4.2	[20]
Rat lens aldose reductase	<i>Zingiber zerumbet</i>	Afzelin	5.54	[21]
Rat lens aldose reductase	<i>Cuminum cyminum</i> (seeds)	Cuminaldehyde	5.9	[6]
Recombinant human aldose reductase	<i>Nephelium lappaceum</i>	Geraniin	7.34	[22]
Rat lens aldose reductase	<i>Cassia tora</i> (seeds)	Chryso-obtusin-2-O- β -D-glucoside	8.8	[23]
		Aurantio-obtusin	13.6	
		Emodin	15.9	
Recombinant human aldose reductase	<i>Paulownia coreana</i>	Isocampneoside II	9.72	[24]
Rat lens aldose reductase	<i>Paeonia suffruticosa</i>	Palbinone	11.4	[25]
		30-norhederagenin	28.8	
Bovine lens aldose reductase	<i>Ganoderma lucidum</i> (fruiting body)	Lucidumol A	19.1	[26]

Current medication: Sorbinil, Fidarestat, Alrestatin, Epalrestat, Tolrestat, Zenarestat.

Note: Some IC₅₀ values are adjusted in terms of molarity to make the comparison convenient.

Table 4S: Inhibition of α -amylase by secondary metabolites

Natural Source	Secondary metabolite	IC ₅₀ value (μ M)	Reference
<i>Ficus deltoidea</i>	Vitexin	0.046	[27]
	Isovitexin	0.138	
<i>Solenostemma argel</i>	Kaempferol-3-O-neohesperidoside	0.08	[28]
<i>Olea europaea</i>	Oleanolic acid	0.219	[29]
<i>Eruca vesicaria</i>	Erucin	0.315	[30]
<i>Ruellia tuberosa</i>	Betulin	0.316	[31]
<i>Citrus paradise</i>	Pectin	2.11	[32]
<i>Abelmoschus esculentus</i>	Proanthocyanidins	3.88	[33]
<i>Phyllanthus amarus</i>	Oleanolic acid+ Ursolic acid	4.4	[34]
<i>Vitex glabrata</i>	β amyryin	32.33	[35]
<i>Rheum turkestanicum</i>	Daucosterol	46.4	[36]
<i>Himatanthus drasticus</i>	Plumieride	71.69	[37]
<i>Vaccinium arctostaphylos</i> (Ericaceae)	Malvidin-3-O-beta-glucoside	329	[38]
<i>Setosphaeria rostrata</i>	Rostratazine B	578	[39]
<i>Psidium guajava</i> (Myrtaceae) Linn.	Myricetin	4300	[40]
	Kaempferol	5300	

Current medication: Acarbose, biguanides, miglitol, voglibose, and 1-deoxynojirimycin.

Note: Some IC₅₀ values are adjusted in terms of molarity to make the comparison convenient.

Table 5S: Inhibition of α -glucosidase by secondary metabolites

Natural Source	Secondary metabolite	IC ₅₀ (μ M)	Reference
<i>Salacia hainanensis</i> Chun	2,3-seco-lup-20(29)en-2,3-dioic acid	0.01	[41]
	Lup-20(29)-en-3,21-dione	0.07	
	30-hydroxy-friedelan-3one	0.08	
	3 α -hydroxy-lup-20(29)-en-2-one	0.09	
<i>Salvia miltiorrhiza</i> Bge	Isosalvianolic acid C methyl ester	111.9 $\times 10^{-3}$	[42]
	Dihydrotanshinone	320.1 $\times 10^{-3}$	
	Isocryptotanshinone	452.1 $\times 10^{-3}$	
<i>Polygonum hyrcanicum</i>	N-trans-Caffeoyl-tyramine	0.3	[43]
	Myricitrin	0.6	
	(-) Gallocatechin	1	
<i>Harungana madagascariensis</i>	Kenganthranols B	6.3	[44]
	Kenganthranols C	21.9	
<i>Punica granatum</i>	Punicatannins A	7.15 \pm 0.27	[45]

Supplementary Materials

	Punicatannins B	12.39 ± 0.05	
<i>Quercus gilva</i>	Tiliroside	28.36	[46]
<i>Euonymus alatus</i> (Twig)	Betulinic acid	83.6	[47]
	Hederagenin	85.3	
	Naringenin	96.8	
	Kaempferol	107.8	
<i>Dryopteris cycadina</i>	3, 5, 7-trihydroxy-2-(<i>p</i> -tolyl) chorman-4-one	133	[48]
<i>Brickellia cavanillesii</i>	β-Sitosterol	143	
	5,7,4'-Trihydroxyflavon-3- glucopyranoid	146	
	Calein C	280	[49]
	6-hydroxyacetyl-5-hydroxy- 2,2-dimethyl-2H-chromene	420	
<i>Aspergillus aculeatus</i>	Aspergillusol A	465	[50]
<i>Uncaria cordata</i>	Querecetin	1840.82	[51]
	2,4-Hydroxybenzoic acid	3652.16	
<i>Ligusticum porter</i>	3-(Z)-butylidenephthalide	2350	[52]

Current medication: Acarbose, miglitol, Voglibose, genistein, quercitrin, and 1-deoxynojirinmycin

Note: Some IC₅₀ values are adjusted in terms of molarity to make the comparison convenient

Table 6S. Prediction of toxicity of secondary metabolites inhibiting metabolic enzymes using ProTox-II

Compound	LD50mg/Kg	Toxicity class	Active target	Probability
(-) gallic acid	10000	6	-	-
(2R)-eriodictyol 7-O- β -D-glucopyranosiduronic acids	2300	5	Immunotoxicity	0.84
(2S)-eriodictyol 7-O- β -D-glucopyranosiduronic acids	2300	5	Immunotoxicity	0.84
1,3,5-Tricaffeoylquinic acid	5000	5	Immunotoxicity	0.97
1,7-bis(4-hydroxyphenyl)-3,5-diol	1600	4	-	-
2-(4-hydroxyphenyl)-ethyl-3,4,5-trihydroxybenzoate	1700	4	Estrogen Receptor Ligand Binding Domain	0.7
2,"4"-O-diacetylquercitrin	5000	5	Immunotoxicity	0.98
2,3-seco-lup-20(29)en-2,3-dioic acid	2500	5	-	-
2,4-hydroxybenzoic acid	2000	4	Carcinogenicity	0.72
3-oxolupenal	5000	5	-	-
3,4,5-tri-O-caffeoylquinic acid	5000	5	Immunotoxicity	0.98
3,4-di-O-caffeoylquinic acid	5000	5	Immunotoxicity	0.99
3,5,7-trihydroxy-2-(p-yolyl)chroman-4-one	2000	4	Aryl hydrocarbon Receptor Aromatase	0.79
			Estrogen Receptor Alpha	0.95
			Estrogen Receptor Ligand Binding Domain	0.88
			Mitochondrial Membrane Potential	0.98
3 α -hydroxy-lup-20(29)-en-2-one	2500	5	-	-
3,5-Di-O-caffeoylquinic acid	5000	5	Immunotoxicity	0.99
3-(z)-butylidenephthalide	1850	4	-	-
4-O-Caffeoylquinic acid	5000	5	Immunotoxicity	0.99
5,7,4-trihydroxyflavon-3-glucopyranoid	5000	5	Immunotoxicity	0.98
6-gingerol	250	3	Immunotoxicity	0.96
6-hydroxyaceyl-5-2,2-dimethyl-2H-chromene	500	4	Immunotoxicity	0.9
12,20-di-O-benzoyl-3 β ,8 β ,12 β ,14 β ,20-pentahydroxy-(20R)-pregn-5-ene-3-O- β -D-glucopyranosyl-(1 \rightarrow 4) β -D-digitaloside	650	4	Immunotoxicity	0.99
(20R)-pregn-5-ene-3-O- β -D-glucopyranosyl-(1 \rightarrow 4) β -D-digitaloside				
30-hydroxy-friedelan-3-one	3265	5	Immunotoxicity	0.84
30-N0rhederagenin	2000	4	Immunotoxicity	0.72
Acarbose (commercial drugs for diabetes)	24000	6	Immunotoxicity	0.9
Acteoside	5000	5	Immunotoxicity	0.99
Afzelin	5000	5	Immunotoxicity	0.92
Aspergillusol A	5000	5	-	-

Supplementary Materials

Aurantio-obtusin	5000	5	Immunotoxicity	0.87
			Mitochondrial Membrane Potential (MMP)	0.85
Avicularin	5000	5	-	-
Azadiradione	600	4	Immunotoxicity	0.85
B2-3'-O-gallate	1000	4	Immunotoxicity	0.98
B- amyrin	7000	6	Immunotoxicity	0.93
β -sitosterol	890	4	Immunotoxicity	0.99
Betulin	2000	4	-	-
Butein	1000	4	Immunotoxicity	0.95
			Aryl hydrocarbon Receptor(ArH)	0.72
			Estrogen Receptor Alpha (ER)	0.96
			Estrogen Receptor Ligand Binding Domain	0.91
			Mitochondrial Membrane potential	0.97
Calein C	7	2	Immunotoxicity	0.99
Chlorogenic acid	5000	5	Immunotoxicity	0.99
chryso-obtusin-2-O- β -D-glucoside	3000	5	Immunotoxicity	0.99
Cuminaldehyde	1320	4	-	-
Daucosterol	8000	6	Immunotoxicity	0.99
Desmethylanhydroicaritin	3919	5	Mitochondrial Membranz Potential (MMP)	0.77
Dihydrotanshinone	260	3	Immunotoxicity	0.98
Emodin	5000	5	Mutagenicity	0.93
			Aryl hydrocarbon Receptor	1
			Estrogen Receptor Alpha	1
			Estrogen Receptor Ligand Binding Domain	1
			Mitochondrial Membrane Potential	0.99
			Phosphoprotein (Tumor Supressor) p53	1
Epalrestat (Commercial drugs for aldol reductase)	5	2	ATPase family AAA domain-containing protein 5	0.98
Erucin	39800	6	No	-
Ganomycin I	2000	4	No	-
Gedunin	2744	3	Immunotoxicity	0.99
Geraniin	122	3	Mutagenicity	0.98
Hederagenin	2000	4	-	-
Hyperoside	5000	5	-	-
Isocampneoside II	5000	5	Immunotoxicity	0.99

Supplementary Materials

Isocryptotanshinone	2000	4	Immunotoxicity	0.89
Isosalvianolic acid C methyl ester	5000	5	Immunotoxicity	0.99
Isoschaftoside	536	4	-	-
Isoscutellarein-8-O-rhamnoside	5000	5	Immunotoxicity	0.86
Isovitexin	159	3	-	-
Kaempferol	3919	5	Aryl hydrocarbon receptor	1
			Aromatase	0.96
			Estrogen Receptor Alpha (ER)	1
			Estrogen Receptor Ligand Binding Domain	0.95
			Mitochondrial Membrane Potential	1
			Immunotoxicity	0.98
			Immunotoxicity	0.97
kaempferol-3-O-neohesperidoside	5000	5	Immunotoxicity	0.98
katononic acid	5000	5	-	-
kenganthranols B	5000	5	Immunotoxicity	0.97
			Mitochondrial Membrane Potential	0.8
			Immunotoxicity	0.96
kenganthranols C	1340	4	Immunotoxicity	0.96
Lucidumol A	1860	4	Carcinogenicity	0.72
lup-20(29)-en-3,21-dione	5000	5	-	-
Lycopene	5000	5	Androgen receptor ligand binding	1
			Estrogen receptor Alpha	1
			Estrogen receptor ligand binding domain	1
			Immunotoxicity	0.98
			Aryl hydrocarbon	0.87
Malvidin-3-O-beta-glucoside	5000	5	Immunotoxicity	0.98
			Aryl hydrocarbon	0.87
			Mitochondrial Membrane Potential	0.79
Methyl xestospongic ester	338	4	-	-
methyl-3,5-di-O-caffeoylquininate	5000	5	Immunotoxicity	0.99
Myricetin	159	3	Aryl hydrocarbon Receptor (AhR)	0.91
			Estrogen Receptor Alpha (ER)	0.87
			Estrogen Receptor Ligand Binding Domain	0.95,
			Mitochondrial Membrane Potential (MMP)	1
			Immunotoxicity	0.95
			Mitochondrial Membrane Potential	0.76
Myricitrin	159	3	Immunotoxicity	0.95
			Mitochondrial Membrane Potential	0.76
			Estrogen Receptor Alpha	0.74
Naringenin	2000	4	Estrogen Receptor Alpha	0.74
			Mitochondrial	0.74

Supplementary Materials

			Membrane Potential	
N-trans-caffeoyl-tyramine	500	4	-	-
Oleanolic acid	159	4	Immunotoxicity	0.79
			Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (nrf2/ARE)	0.7
			Heat shock factor response element (HSE)	0.7
Orientin	5000	5	-	-
Orlistat (commercial drugs for lipase)	1300	4	Hepatotoxicity	0.7
Papyriflavonol A	5000	5	Immunotoxicity	0.92
			Mitochondrial	0.73
			Membrane Potential	
Palbinone	4000		Immunotoxicity	0.95
			Androgen receptor (AR)	0.75
Pectin	10000	6	-	-
Plumieride	2000	4	Immunotoxicity	0.93
Proanthocyanidins	2500	5	Immunotoxicity	0.98
punicatannins A	419	4	Immunotoxicity	0.99
purpurolide D	3220	5	-	-
purpurolide E	3220	5	-	-
purpurolide F	3220	5	-	-
Quercetin	159	3	Aryl hydrocarbon Receptor (AhR)	0.91
			Estrogen Receptor Alpha (ER)	0.87
			Estrogen Receptor Ligand Binding Domain	0.95
			Mitochondrial	1
			Membrane Potential	
Quercitrin	5000	5	Immunotoxicity	0.97
			Immunotoxicity	0.97
Rosamarinate acid	5000	5	Immunotoxicity	0.93
Rostratazine B	3549	5	-	-
Schaftoside	2000	4	-	-
Semilicoisoflavone B	3850	5	-	-
Sinigrin	15	2	-	-
Tectoridin	5000	5	Immunotoxicity	0.95
Tectorigenin	2500	5	Immunotoxicity	0.71
			Aryl hydrocarbon Receptor (AhR)	0.97
			Estrogen Receptor Alpha (ER)	0.88
			Estrogen Receptor Ligand Binding	0.89

Supplementary Materials

			Domain	
			Mitochondrial	0.92
			Membrane Potential	
			(MMP)	
Tiliroside	5000	5	Immunotoxicity	0.97
Ursolic acid	2000	4	Immunotoxicity	0.95
			Nuclear factor	0.7
			(erythroid-derived	
			2)-like 2/antioxidant	
			responsive element	
			(nrf2/ARE)	
			Heat shock factor	0.7
			response element	
			(HSE)	
Vicenin-1	536	4	-	-
Vitexin	1213	4	-	-




Figure 1S. Enzymatic reactions catalysed by α -amylase, α -glucosidase, aldose reductase and lipase.

Reference

- [1] G.-Y. Xia *et al.*, "Three new polyoxygenated bergamotanes from the endophytic fungus *Penicillium purpurogenum* IMM 003 and their inhibitory activity against pancreatic lipase," *Chin. J. Nat. Med.*, vol. 18, no. 1, pp. 75–80, Jan. 2020, doi: 10.1016/S1875-5364(20)30007-8.
- [2] L.-F. Liang *et al.*, "Brominated polyunsaturated lipids from the Chinese sponge *Xestospongia testudinaria* as a new class of pancreatic lipase inhibitors," *Eur. J. Med. Chem.*, vol. 79, pp. 290–297, May 2014, doi: 10.1016/j.ejmech.2014.04.003.
- [3] A. A. Shalabi *et al.*, "New pregnane glycosides from *Caralluma hexagona* Lavranos and their in vitro α -glucosidase and pancreatic lipase inhibitory effects," *Phytochem. Lett.*, vol. 36, pp. 49–57, Apr. 2020, doi: 10.1016/j.phytol.2020.01.015.
- [4] J.-Y. Park, C. S. Kim, K.-M. Park, and P.-S. Chang, "Inhibitory characteristics of flavonol-3-O-glycosides from *Polygonum aviculare* L. (common knotgrass) against porcine pancreatic lipase," *Sci. Rep.*, vol. 9, no. 1, p. 18080, Dec. 2019, doi: 10.1038/s41598-019-54546-8.
- [5] W. I. T. Fernando *et al.*, "Isolation, identification and characterization of pancreatic lipase inhibitors from *Trigonella foenum-graecum* seeds," *South Afr. J. Bot.*, vol. 121, pp. 418–421, Mar. 2019, doi: 10.1016/j.sajb.2018.10.023.
- [6] H.-S. Lee, "Cuminaldehyde: Aldose Reductase and α -Glucosidase Inhibitor Derived from *Cuminum cyminum* L. Seeds," *J. Agric. Food Chem.*, vol. 53, no. 7, pp. 2446–2450, Apr. 2005, doi: 10.1021/jf048451g.
- [7] I.-S. Lee, I. S. Kim, Y. M. Lee, Y. Lee, J.-H. Kim, and J. S. Kim, "2",4"-O-Diacetylquercitrin, a Novel Advanced Glycation End-Product Formation and Aldose Reductase Inhibitor from *Melastoma sanguineum*," *Chem. Pharm. Bull. (Tokyo)*, vol. 61, no. 6, pp. 662–665, 2013, doi: 10.1248/cpb.c12-00877.
- [8] H. A. Jung *et al.*, "Extraction and identification of three major aldose reductase inhibitors from *Artemisia montana*," *Food Chem. Toxicol.*, vol. 49, no. 2, pp. 376–384, Feb. 2011, doi: 10.1016/j.fct.2010.11.012.
- [9] H. N. Yoon, M. Y. Lee, J.-K. Kim, H.-W. Suh, and S. S. Lim, "Aldose Reductase Inhibitory Compounds from *Xanthium strumarium*," *Arch. Pharm. Res.*, vol. 36, no. 9, pp. 1090–1095, Sep. 2013, doi: 10.1007/s12272-013-0123-5.
- [10] H. A. Jung, N. Y. Yoon, S. S. Kang, Y. S. Kim, and J. S. Choi, "Inhibitory activities of prenylated flavonoids from *Sophora flavescens* against aldose reductase and generation of advanced glycation endproducts," *J. Pharm. Pharmacol.*, vol. 60, no. 9, pp. 1227–1236, Sep. 2008, doi: 10.1211/jpp.60.9.0016.
- [11] E. H. Lee, D.-G. Song, J. Y. Lee, C.-H. Pan, B. H. Um, and S. H. Jung, "Inhibitory Effect of the Compounds Isolated from *Rhus verniciflua* on Aldose Reductase and Advanced Glycation Endproducts," *Biol. Pharm. Bull.*, vol. 31, no. 8, pp. 1626–1630, 2008, doi: 10.1248/bpb.31.1626.
- [12] H. Lee, J. Kim, and W. Whang, "Chemical Constituents of *Smilax china* L. Stems and Their Inhibitory Activities against Glycation, Aldose Reductase, α -Glucosidase, and Lipase," *Molecules*, vol. 22, no. 3, p. 451, Mar. 2017, doi: 10.3390/molecules22030451.
- [13] S. H. Jung, Y. S. Lee, S. Lee, S. S. Lim, Y. S. Kim, and K. H. Shin, "Isoflavonoids from the rhizomes of *Belamcanda chinensis* and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues," *Arch. Pharm. Res.*, vol. 25, no. 3, pp. 306–312, Jun. 2002, doi: 10.1007/BF02976631.
- [14] H. M. Li, J. K. Kim, J. M. Jang, C. B. Cui, and S. S. Lim, "Analysis of the inhibitory activity of *Abeliophyllum distichum* leaf constituents against aldose reductase by using high-speed counter current chromatography," *Arch. Pharm. Res.*, vol. 36, no. 9, pp. 1104–1112, Sep. 2013, doi: 10.1007/s12272-013-0127-1.
- [15] H. Matsuda, T. Morikawa, I. Toguchida, S. Harima, and M. Yoshikawa, "Medicinal Flowers. VI. Absolute Stereostructures of Two New Flavanone Glycosides and a Phenylbutanoid Glycoside from the Flowers of *Chrysanthemum indicum* L.: Their Inhibitory Activities for Rat Lens Aldose Reductase," *Chem. Pharm. Bull. (Tokyo)*, vol. 50, no. 7, pp. 972–975, 2002, doi: 10.1248/cpb.50.972.

- [16] H. Li, S. Hwang, B. Kang, J. Hong, and S. Lim, "Inhibitory Effects of *Colocasia esculenta* (L.) Schott Constituents on Aldose Reductase," *Molecules*, vol. 19, no. 9, pp. 13212–13224, Aug. 2014, doi: 10.3390/molecules190913212.
- [17] C.-B. Cui, "Inhibitory Activity of Caffeoylquinic Acids from the Aerial Parts of *Artemisia princeps* on Rat Lens Aldose Reductase and on the Formation of Advanced Glycation End Products," *J. Korean Soc. Appl. Biol. Chem.*, vol. 52, no. 6, pp. 655–662, Dec. 2009, doi: 10.3839/jksabc.2009.109.
- [18] Y. S. Lee, S. H. Kim, S. H. Jung, J. K. Kim, C.-H. Pan, and S. S. Lim, "Aldose Reductase Inhibitory Compounds from *Glycyrrhiza uralensis*," *Biol. Pharm. Bull.*, vol. 33, no. 5, pp. 917–921, 2010, doi: 10.1248/bpb.33.917.
- [19] H. A. Bhatti *et al.*, "Identification of new potent inhibitor of aldose reductase from *Ocimum basilicum*," *Bioorganic Chem.*, vol. 75, pp. 62–70, Dec. 2017, doi: 10.1016/j.bioorg.2017.08.011.
- [20] S. B. Kim, S. H. Hwang, Z. Wang, J. M. Yu, and S. S. Lim, "Rapid Identification and Isolation of Inhibitors of Rat Lens Aldose Reductase and Antioxidant in *Maackia amurensis*," *BioMed Res. Int.*, vol. 2017, pp. 1–10, 2017, doi: 10.1155/2017/4941825.
- [21] K. R. Ajish *et al.*, "Studies on α -glucosidase, aldose reductase and glycation inhibitory properties of sesquiterpenes and flavonoids of *Zingiber zerumbet* Smith," *Nat. Prod. Res.*, vol. 29, no. 10, pp. 947–952, May 2015, doi: 10.1080/14786419.2014.956741.
- [22] U. D. Palanisamy, L. T. Ling, T. Manaharan, and D. Appleton, "Rapid isolation of geraniin from *Nephelium lappaceum* rind waste and its anti-hyperglycemic activity," *Food Chem.*, vol. 127, no. 1, pp. 21–27, Jul. 2011, doi: 10.1016/j.foodchem.2010.12.070.
- [23] D. S. Jang *et al.*, "Anthraquinones from the Seeds of *Cassia tora* with Inhibitory Activity on Protein Glycation and Aldose Reductase," *Biol. Pharm. Bull.*, vol. 30, no. 11, pp. 2207–2210, 2007, doi: 10.1248/bpb.30.2207.
- [24] J. K. Kim, Y. S. Lee, S. H. Kim, Y. S. Bae, and S. S. Lim, "Inhibition of Aldose Reductase by Phenylethanoid Glycoside Isolated from the Seeds of *Paulownia coreana*," *Biol. Pharm. Bull.*, vol. 34, no. 1, pp. 160–163, 2011, doi: 10.1248/bpb.34.160.
- [25] D. T. Ha *et al.*, "Inhibitors of Aldose Reductase and Formation of Advanced Glycation End-Products in Moutan Cortex (*Paeonia suffruticosa*)," *J. Nat. Prod.*, vol. 72, no. 8, pp. 1465–1470, Aug. 2009, doi: 10.1021/np9002004.
- [26] B. Chen *et al.*, "Triterpenes and meroterpenes from *Ganoderma lucidum* with inhibitory activity against HMGs reductase, aldose reductase and α -glucosidase," *Fitoterapia*, vol. 120, pp. 6–16, Jul. 2017, doi: 10.1016/j.fitote.2017.05.005.
- [27] A. R. Abu Bakar, T. Manaharan, A. F. Merican, and S. B. Mohamad, "Experimental and computational approaches to reveal the potential of *Ficus deltoidea* leaves extract as α -amylase inhibitor," *Nat. Prod. Res.*, vol. 32, no. 4, pp. 473–476, Feb. 2018, doi: 10.1080/14786419.2017.1312393.
- [28] R. A. El-shiekh, D. A. Al-Mahdy, M. S. Hifnawy, and E. A. Abdel-Sattar, "In-vitro screening of selected traditional medicinal plants for their anti-obesity and anti-oxidant activities," *South Afr. J. Bot.*, vol. 123, pp. 43–50, Jul. 2019, doi: 10.1016/j.sajb.2019.01.022.
- [29] E. Komaki *et al.*, "Identification of Anti- α -Amylase Components from Olive Leaf Extracts," *Food Sci. Technol. Res.*, vol. 9, no. 1, pp. 35–39, 2003, doi: 10.3136/fstr.9.35.
- [30] F. Hichri, A. Omri, A. S. M. Hossan, and H. Ben Jannet, "Alpha-glucosidase and amylase inhibitory effects of *Eruca vesicaria* subsp. *longirostris* essential oils: synthesis of new 1,2,4-triazole-thiol derivatives and 1,3,4-thiadiazole with potential inhibitory activity," *Pharm. Biol.*, vol. 57, no. 1, pp. 564–570, Jan. 2019, doi: 10.1080/13880209.2019.1642363.

- [31] D. Ratna Wulan, E. Priyo Utomo, and C. Mahdi, "Antidiabetic Activity of *Ruellia tuberosa* L., Role of α -Amylase Inhibitor: *In Silico*, *In Vitro*, and *In Vivo* Approaches," *Biochem. Res. Int.*, vol. 2015, pp. 1–9, 2015, doi: 10.1155/2015/349261.
- [32] A. L. de la Garza *et al.*, "Helichrysum and Grapefruit Extracts Inhibit Carbohydrate Digestion and Absorption, Improving Postprandial Glucose Levels and Hyperinsulinemia in Rats," *J. Agric. Food Chem.*, vol. 61, no. 49, pp. 12012–12019, Dec. 2013, doi: 10.1021/jf4021569.
- [33] Y. Lu, M. F. Demleitner, L. Song, M. Rychlik, and D. Huang, "Oligomeric proanthocyanidins are the active compounds in *Abelmoschus esculentus* Moench for its α -amylase and α -glucosidase inhibition activity," *J. Funct. Foods*, vol. 20, pp. 463–471, Jan. 2016, doi: 10.1016/j.jff.2015.10.037.
- [34] H. Ali, P. J. Houghton, and A. Soumyanath, " α -Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to *Phyllanthus amarus*," *J. Ethnopharmacol.*, vol. 107, no. 3, pp. 449–455, Oct. 2006, doi: 10.1016/j.jep.2006.04.004.
- [35] S. Thengyai, P. Thiantongin, C. Sontimuang, C. Ovatlarnporn, and P. Puttarak, " α -Glucosidase and α -amylase inhibitory activities of medicinal plants in Thai antidiabetic recipes and bioactive compounds from *Vitex glabrata* R. Br. stem bark," *J. Herb. Med.*, vol. 19, p. 100302, Feb. 2020, doi: 10.1016/j.hermed.2019.100302.
- [36] H. Dehghan, P. Salehi, and M. S. Amiri, "Bioassay-guided purification of α -amylase, α -glucosidase inhibitors and DPPH radical scavengers from roots of *Rheum turkestanicum*," *Ind. Crops Prod.*, vol. 117, pp. 303–309, Jul. 2018, doi: 10.1016/j.indcrop.2018.02.086.
- [37] F. S. Morais *et al.*, "Chemical profiling of secondary metabolites from *Himatanthus drasticus* (Mart.) Plumel latex with inhibitory action against the enzymes α -amylase and α -glucosidase: In vitro and in silico assays," *J. Ethnopharmacol.*, vol. 253, p. 112644, May 2020, doi: 10.1016/j.jep.2020.112644.
- [38] B. Nickavar and G. Amin, "Enzyme Assay Guided Isolation of an α -Amylase Inhibitor Flavonoid from *Vaccinium arctostaphylos* Leaves," *Iran. J. Pharm. Res. IJPR*, vol. 10, no. 4, pp. 849–853, 2011.
- [39] R. M. Centko, P. B. Ratnaweera, C. Tysoe, S. G. Withers, E. D. de Silva, and R. J. Andersen, "Alpha-glucosidase and alpha-amylase inhibiting thiodiketopiperazines from the endophytic fungus *Setosphaeria rostrata* isolated from the medicinal plant *Costus speciosus* in Sri Lanka," *Phytochem. Lett.*, vol. 22, pp. 76–80, Dec. 2017, doi: 10.1016/j.phytol.2017.09.004.
- [40] H. Wang, Y.-J. Du, and H.-C. Song, " α -Glucosidase and α -amylase inhibitory activities of guava leaves," *Food Chem.*, vol. 123, no. 1, pp. 6–13, Nov. 2010, doi: 10.1016/j.foodchem.2010.03.088.
- [41] H.-Y. Gao, Z.-H. Guo, P. Cheng, X.-M. Xu, and L.-J. Wu, "New triterpenes from *Salacia hainanensis* Chun et How with α -glucosidase inhibitory activity," *J. Asian Nat. Prod. Res.*, vol. 12, no. 10, pp. 834–842, Oct. 2010, doi: 10.1080/10286020.2010.503653.
- [42] H.-Y. Ma, H.-Y. Gao, L. Sun, J. Huang, X.-M. Xu, and L.-J. Wu, "Constituents with α -glucosidase and advanced glycation end-product formation inhibitory activities from *Salvia miltiorrhiza* Bge.," *J. Nat. Med.*, vol. 65, no. 1, pp. 37–42, Jan. 2011, doi: 10.1007/s11418-010-0453-2.
- [43] F. Moradi-Afrapoli *et al.*, "In vitro α -glucosidase inhibitory activity of phenolic constituents from aerial parts of *Polygonum hyrcanicum*," *DARU J. Pharm. Sci.*, vol. 20, no. 1, p. 37, Dec. 2012, doi: 10.1186/2008-2231-20-37.
- [44] S. F. Kouam *et al.*, " α -Glucosidase Inhibitory Anthranols, Kenganthranols A–C, from the Stem Bark of *Harungana m adagascariensis*," *J. Nat. Prod.*, vol. 69, no. 2, pp. 229–233, Feb. 2006, doi: 10.1021/np050407n.
- [45] T. Yuan *et al.*, "Antidiabetic Ellagitannins from Pomegranate Flowers: Inhibition of α -Glucosidase and Lipogenic Gene Expression," *Org. Lett.*, vol. 14, no. 20, pp. 5358–5361, Oct. 2012, doi: 10.1021/ol302548c.

Supplementary Materials

- [46] A. W. Indrianingsih, S. Tachibana, R. T. Dewi, and K. Itoh, "Antioxidant and α -glucosidase inhibitor activities of natural compounds isolated from *Quercus gilva* Blume leaves," *Asian Pac. J. Trop. Biomed.*, vol. 5, no. 9, pp. 748–755, Sep. 2015, doi: 10.1016/j.apjtb.2015.07.004.
- [47] C.-I. Choi, S. R. Lee, and K. H. Kim, "Antioxidant and α -glucosidase inhibitory activities of constituents from *Euonymus alatus* twigs," *Ind. Crops Prod.*, vol. 76, pp. 1055–1060, Dec. 2015, doi: 10.1016/j.indcrop.2015.08.031.
- [48] S. Amin *et al.*, "Potent in Vitro α -Glucosidase Inhibition of Secondary Metabolites Derived from *Dryopteris cycadina*," *Molecules*, vol. 24, no. 3, p. 427, Jan. 2019, doi: 10.3390/molecules24030427.
- [49] S. Escandón-Rivera, M. González-Andrade, R. Bye, E. Linares, A. Navarrete, and R. Mata, " α -Glucosidase Inhibitors from *Brickellia cavanillesii*," *J. Nat. Prod.*, vol. 75, no. 5, pp. 968–974, May 2012, doi: 10.1021/np300204p.
- [50] N. Ingavat, J. Dobereiner, S. Wiyakrutta, C. Mahidol, S. Ruchirawat, and P. Kittakoop, "Aspergillusol A, an α -Glucosidase Inhibitor from the Marine-Derived Fungus *Aspergillus aculeatus*," *J. Nat. Prod.*, vol. 72, no. 11, pp. 2049–2052, Nov. 2009, doi: 10.1021/np9003883.
- [51] N. Abdullah, F. Salim, and R. Ahmad, "Chemical Constituents of Malaysian *U. cordata* var. *ferruginea* and Their in Vitro α -Glucosidase Inhibitory Activities," *Molecules*, vol. 21, no. 5, p. 525, Apr. 2016, doi: 10.3390/molecules21050525.
- [52] F. Brindis, R. Rodríguez, R. Bye, M. González-Andrade, and R. Mata, "(*Z*)-3-Butylidenephthalide from *Ligusticum porteri*, an α -Glucosidase Inhibitor," *J. Nat. Prod.*, vol. 74, no. 3, pp. 314–320, Mar. 2011, doi: 10.1021/np100447a.